Cannabis and cannabis-derived products are at a legal and regulatory crossroads at both the federal and state levels. This conference will examine the present and proposed regulatory schemes and concerns for this unique industry that impacts many FDA regulated product categories. Experts from across the country and abroad will also discuss practical concerns for entities attempting to navigate this continually evolving legal environment.
Conference Highlights:
- Updates on federal legislation and regulation, plus recent state-level developments.
- Analysis of the legal status of Cannabidiol (CBD), Delta-8 tetrahydrocannabinol (THC), and other hemp-derived substances.
- Outlook for both medical marijuana and cannabinoid ingredients in foods, dietary supplements, and cosmetics.
Call for Proposals
FDLI and the Conference Planning Committee thanks those who participated in the Call for Proposals. The input received from industry stakeholders helps us plan a timely program. If you submitted a proposal, you will be notified of the status of your proposal in April 2022.
Register!
Industry & Firms
- +$200 for non-members
Government
- +$100 for non-members
Non-Profit
- +$100 for non-members
Academic
- +$100 for non-members
Sponsors
Sponsorship opportunities are available, learn more. For more information, contact Cathy Kiss.
Planning Committee
Holly J. Bayne, Law Office of Bayne & Associates
Rodney William Butt, Nutrasource Pharmaceutical & Nutraceutical Services
Sarah A Chase, Council for Federal Cannabis Regulation (CFCR)
Amanda Cowley, U.S. Pharmacopeia
Marshall A. Custer, Husch Blackwell LLP
Kay Doyle, Greenwich Biosciences
William Garvin, Buchanan Ingersoll & Rooney PC
Jae Kim, DLA Piper LLP (US)
Andrew Kline, Perkins Coie LLP
Dan Logan, Kleinfeld, Kaplan & Becker, LLP
Deborah Miran, DMiran Consulting
Teresa Reguly, Torys LLP
Daniel Rubenstein, Steptoe & Johnson LLP
Frederick A. Stearns, Keller and Heckman LLP
Elizabeth Butterworth Stutts, Elizabeth Butterworth Stutts, Esq, PLLC
